Back

Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator

8 April 2024 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Arrhythmias 12: atrial fibrillation Antiarrhythmic Drug Treatment EHRA Premium Access EHRA 2024 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Maura Magdalena Zylla

University Hospital Heidelberg, Heidelberg (Germany)

8 More presentations in this session

Presentation thumbnail
Staged hybrid convergent procedure versus pulsed field ablation for pulmonary veins and posterior wall isolation in the treatment of atrial fibrillation
Doctor E. Zito (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Feasibility and determinants of short-term heart rate variability in patients using photoplethysmography-based wearable devices - data derived from TeleCheck-AF
Doctor H. Hillmann (Hannover, DE)
Abstract Slides Video
Presentation thumbnail
Exploration of peak frequency mapping for ventricular tachycardia ablation. Identification of critical isthmus zones during substrate mapping
Mr J. Mayer (Stoke-on-Trent, GB)
Abstract Slides Video
Presentation thumbnail
Electrocardiographic characteristics and catheter ablation of premature ventricular complex- mediated ventricular fibrillation
Doctor A. Maan (Toledo, US)
Abstract Slides Video
Presentation thumbnail
Preliminary implantation experience in Europe with a novel insertable cardiac monitor
Doctor S. Fareh (Lyon, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Arrhythmias 12: atrial fibrillation

The Event

Event poster

EHRA 2024

8 April 2024 15:30 CET
You may be interested in
thumbnail
Congress Presentation
Use of class ic antiarrhythmic drugs in atrial fibrillation with structural heart disease: a nationwide cohort study
thumbnail
Congress Presentation
Implantable cardioverter defibrillators in heart failure with reduced ejection fraction: evaluating efficacy in the era of contemporary pharmacotherapy
thumbnail
Congress Presentation
Implantable cardioverter-defibrillator therapies in primary prevention are not decreased in a contemporary cohort: insights from long-term follow-up

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources